583 related articles for article (PubMed ID: 30061509)
1. Tackling the Antibiotic Resistance Caused by Class A
Eiamphungporn W; Schaduangrat N; Malik AA; Nantasenamat C
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061509
[TBL] [Abstract][Full Text] [Related]
2. Engineering Specificity from Broad to Narrow: Design of a β-Lactamase Inhibitory Protein (BLIP) Variant That Exclusively Binds and Detects KPC β-Lactamase.
Chow DC; Rice K; Huang W; Atmar RL; Palzkill T
ACS Infect Dis; 2016 Dec; 2(12):969-979. PubMed ID: 27756125
[TBL] [Abstract][Full Text] [Related]
3. Insight into Structure-Function Relationships of β-Lactamase and BLIPs Interface Plasticity using Protein-Protein Interactions.
Yadav TC; Agarwal V; Srivastava AK; Raghuwanshi N; Varadwaj P; Prasad R; Pruthi V
Curr Pharm Des; 2019; 25(31):3378-3389. PubMed ID: 31544712
[TBL] [Abstract][Full Text] [Related]
4. Cyclic Boronates Inhibit All Classes of β-Lactamases.
Cahill ST; Cain R; Wang DY; Lohans CT; Wareham DW; Oswin HP; Mohammed J; Spencer J; Fishwick CW; McDonough MA; Schofield CJ; Brem J
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115348
[TBL] [Abstract][Full Text] [Related]
5. Interdomain flexibility and interfacial integrity of β-lactamase inhibitory protein (BLIP) modulate its binding to class A β-lactamases.
Huang L; So PK; Chen YW; Leung YC; Yao ZP
J Biol Chem; 2021 Aug; 297(2):100980. PubMed ID: 34302811
[TBL] [Abstract][Full Text] [Related]
6. Class A β-lactamases and inhibitors: In silico analysis of the binding mode and the relationship with resistance.
Pereira R; Rabelo VW; Sibajev A; Abreu PA; Castro HC
J Biotechnol; 2018 Aug; 279():37-46. PubMed ID: 29753682
[TBL] [Abstract][Full Text] [Related]
7. β-Lactamase inhibitor peptides as the new strategies to overcome bacterial resistance.
Silva ON; Franco OL; Porto WF
Drugs Today (Barc); 2018 Dec; 54(12):737-746. PubMed ID: 30596392
[TBL] [Abstract][Full Text] [Related]
8. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the discovery of metallo-β-lactamase inhibitors for β-lactam antibiotic-resistant reversing agents.
Guo Z; Ma S
Curr Drug Targets; 2014; 15(7):689-702. PubMed ID: 24666360
[TBL] [Abstract][Full Text] [Related]
10. New promising β-lactamase inhibitors for clinical use.
Olsen I
Eur J Clin Microbiol Infect Dis; 2015 Jul; 34(7):1303-8. PubMed ID: 25864193
[TBL] [Abstract][Full Text] [Related]
11. Progress toward inhibitors of metallo-β-lactamases.
McGeary RP; Tan DT; Schenk G
Future Med Chem; 2017 May; 9(7):673-691. PubMed ID: 28504895
[TBL] [Abstract][Full Text] [Related]
12. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
Rotschafer JC; Ostergaard BE
Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
[TBL] [Abstract][Full Text] [Related]
13. Three decades of beta-lactamase inhibitors.
Drawz SM; Bonomo RA
Clin Microbiol Rev; 2010 Jan; 23(1):160-201. PubMed ID: 20065329
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
15. An update on β-lactamase inhibitor discovery and development.
Docquier JD; Mangani S
Drug Resist Updat; 2018 Jan; 36():13-29. PubMed ID: 29499835
[TBL] [Abstract][Full Text] [Related]
16. Identification of the β-lactamase inhibitor protein-II (BLIP-II) interface residues essential for binding affinity and specificity for class A β-lactamases.
Brown NG; Chow DC; Ruprecht KE; Palzkill T
J Biol Chem; 2013 Jun; 288(24):17156-66. PubMed ID: 23625930
[TBL] [Abstract][Full Text] [Related]
17. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
[TBL] [Abstract][Full Text] [Related]
18. Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms.
Martin JF; Alvarez-Alvarez R; Liras P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628478
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of antibiotic resistance and beta-lactamase inhibition by mechanism-based inactivators: perspectives and future directions.
Therrien C; Levesque RC
FEMS Microbiol Rev; 2000 Jul; 24(3):251-62. PubMed ID: 10841972
[TBL] [Abstract][Full Text] [Related]
20. Docking and Molecular Dynamic of Microalgae Compounds as Potential Inhibitors of Beta-Lactamase.
Pestana-Nobles R; Aranguren-Díaz Y; Machado-Sierra E; Yosa J; Galan-Freyle NJ; Sepulveda-Montaño LX; Kuroda DG; Pacheco-Londoño LC
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
